Trade Precision BioSciences, Inc. - DTIL CFD

About Precision BioSciences Inc

Precision BioSciences, Inc is a clinical stage biotechnology company. The Company’s ARCUS platform is designed to deliver therapeutic-grade genome editing. Its ARCUS genome editing technology is for deoxyribonucleic acid (DNA) genome insertion, deletion and repair. Its ARCUS is based on a naturally occurring genome editing enzyme, I-CreI, that evolved in the algae Chlamydomonas reinhardtii to make specific cuts and DNA insertions in cellular DNA. The Company’s pipeline includes Ex vivo Allogeneic CAR T Immunotherapy and In vivo Gene Correction. Its Ex vivo Allogeneic CAR T Immunotherapy pipeline offers programs, including PBCAR0191, PBCAR19B, PBCAR269A and CD19 Combination with Foralumab. Its in-vivo Gene Correction pipeline offers three preclinical programs, including PBGENE-PCSK9, PBGENE-PH1 and PBGENE-HBV. The Company’s subsidiaries include Precision PlantSciences, Inc. and Precision BioSciences UK Limited.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Precision BioSciences Inc revenues increased from $24.3M to $115.5M. Net loss decreased 72% to $30.6M. Revenues reflect Therapeutics segment increase from $21.9M to $111.7M, Food segment increase of 57% to $3.8M. Lower net loss reflects Therapeutics segment income totaling $32M vs. loss of $50M, Food segment loss decrease of 26% to $3.8M.